Clinical-stage biotech using lysosome-targeting LYTAC molecules to clear disease-causing proteins, starting with allergy and Graves' disease.
Clinical-stage biotech using lysosome-targeting LYTAC molecules to clear disease-causing proteins, starting with allergy and Graves' disease.
Has no product revenue yet, so it funds early-stage trials from investor capital, including its October 2026 Nasdaq IPO. Its method uses lysosomes, the cell's disposal units, to clear disease-causing proteins from the bloodstream, aimed first at the antibody IgE in food allergy and at Graves' disease autoantibodies. Both lead drugs are in Phase 1.
Moat: narrow (IP / patents). Platform patents on a first-of-its-kind mechanism; clinical proof is still early.
Headquarters: South San Francisco, United States · Founded: 2019
Size Lycia Therapeutics (LYCA) is a United States Health Care company (Biotechnology) with a market value of $1.81B, the 1844th largest of 3,085 United States companies the cockpit tracks. Shares closed at $31.35 on 18 Nov 2026.
Growth Revenue fell 54.9% over the last twelve months (peer median +16.6%); the operating margin is -593.4% (peer median -0.2%).
Short interest Short interest is 0.5% of the free float (30 Oct 2026).
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | n/a | $6.74M | $14.9M |
| Revenue growth | — | -55% | — |
| Gross profit | n/a | $3.91M | $12.6M |
| EBITDA | n/a | -$37.2M | -$30.1M |
| Net income | n/a | -$36.5M | -$26.5M |
| Free cash flow | n/a | -$51.6M | -$30.8M |
| Capital expenditure | n/a | $194,000 | $1.27M |
| Total debt | n/a | $205M | $207M |
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Lycia Therapeutics LYCA | $1.81B | n/a | -55% | -593% | n/a | n/a |
| Immunovant IMVT | $6.86B | -7% | n/a | n/a | n/a | n/a |
| argenx SE Sponsored ADR ARGX | $59.1B | +17% | +71% | 29% | 10.3× | 11.7% |
| Kymera Therapeutics KYMR | $10.3B | +50% | +134% | -396% | 92.4× | n/a |
| Arvinas ARVN | $443M | -26% | -12% | -10% | n/a | n/a |
| Roche RO.SW | $381B | +21% | -1% | 31% | 5.7× | 1.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | LYCA | Peer median | Rank in peer set |
|---|---|---|---|
| Distance from 52-week high | -14.1% | -34.3% | highest of 21 |
| Revenue growth (TTM) | -54.9% | +16.6% | 3rd lowest of 16 |
| Operating margin | -593.4% | -0.2% | 5th lowest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Lycia Therapeutics LYCA | United States | $1.81B | n/a | -55% | -593% | n/a | n/a | n/a |
| Zenas BioPharma ZBIO | United States | $1.79B | +35% | -27% | -2,748% | 146.1× | n/a | n/a |
| Hemab Therapeutics COAG | United States | $1.83B | +48% | n/a | n/a | n/a | n/a | n/a |
| GemPharmatech 688046.SS | China | $1.78B | +39% | +25% | 22% | 11.7× | 33.0% | +24.8% |
| Vera Therapeutics VERA | United States | $1.85B | -26% | n/a | -4,160% | 149.9× | n/a | n/a |
| Recursion Pharmaceuticals RXRX | United States | $1.76B | -5% | +56% | -725% | 18.8× | n/a | n/a |
| Shenzhen Kangtai Biological Products 300601.SZ | China | $1.86B | -20% | -9% | 6% | 4.9× | 22.7% | +3.4% |
| First Tracks Biotherapeutics TRAX | United States | $1.87B | +175% | n/a | n/a | n/a | n/a | n/a |
| Stoke Therapeutics STOK | United States | $1.75B | -12% | -86% | -913% | 50.6× | n/a | n/a |
| Septerna SEPN | United States | $1.88B | +41% | +337% | -76% | 14.7× | n/a | n/a |
| Replimune REPL | United States | $1.88B | +321% | n/a | n/a | n/a | n/a | n/a |
| BioCryst Pharmaceuticals BCRX | United States | $1.88B | -16% | +60% | 42% | 2.4× | -11.0% | +117.9% |
| Sinocelltech 688520.SS | China | $1.90B | -35% | -40% | -75% | 13.6× | n/a | n/a |
| Maravai Lifesciences MRVI | United States | $1.92B | +101% | +11% | -17% | 10.2× | n/a | n/a |
| Trevi Therapeutics TRVI | United States | $1.93B | -3% | n/a | n/a | n/a | n/a | n/a |
| Hugel 145020.KS | South Korea | $1.69B | -30% | +17% | 38% | 3.6× | -12.1% | +15.0% |
| Immunome IMNM | United States | $1.98B | -22% | -100% | n/a | n/a | n/a | n/a |
| Zhejiang Hengtong 600226.SS | China | $1.64B | -31% | +71% | 0% | 4.2× | n/a | n/a |
| ANI Pharmaceuticals ANIP | United States | $1.62B | -13% | +26% | 15% | 1.7× | -7.6% | +33.5% |
| Alvotech ALVO | United States | $1.62B | +38% | -14% | 12% | 6.4× | n/a | n/a |
| Hitgen 688222.SS | China | $1.62B | -3% | +42% | 27% | 14.4× | 33.2% | +16.8% |